Product
Nanoliposomal-Irinotecan
1 clinical trial
1 indication
Indication
Bile Duct CancerClinical trial
A Single Arm Phase Ib/II Multi-Center Study of Nivolumab in Combination With Nanoliposomal-Irinotecan, 5-Fluorouracil, and Leucovorin as Second Line Therapy for Patients With Advanced Biliary Tract CancerStatus: Active (not recruiting), Estimated PCD: 2025-05-01